JP5416232B2 - Hematological sample measuring device - Google Patents

Description

The present invention relates to a measuring TeiSo location of hematological sample, immature leukocytes, and in particular to measuring TeiSo location of hematological sample can be counted to distinguish myeloblasts in other blood cells and high accuracy.

The cellular components of blood are roughly classified into platelets, white blood cells, and red blood cells, and white blood cells are further classified into granulocytes (eosinophils, neutrophils, and basophils), monocytes, and lymphocytes.
These cells are made in the bone marrow, differentiate and mature from immature cells, and migrate to peripheral blood. In healthy individuals, young leukocytes (young leukocytes) that are not matured into normal white blood cells such as granulocytes, monocytes, and lymphocytes (hereinafter sometimes referred to as “mature leukocytes”) Does not appear in peripheral blood, but immature leukocytes such as myeloblasts may appear in the peripheral blood of patients with leukemia, bone marrow metastasis of cancer, severe infections, and the like. In particular, detecting myeloblasts is important in diagnosing the above-mentioned diseases.

  A measurement method using flow cytometry is used as a method for automatically measuring blood collected in clinical examinations, medical examinations, and the like. In flow cytometry, a sample stained with a cell membrane or nucleus is introduced into the flow cell, and the cells passing through the flow cell are irradiated with dye excitation light, and scattered light or fluorescence emitted from individual cells passing through the flow cell. Is obtained, and the type and number of cells are measured from this information.

  In the method of measuring hematological samples using flow cytometry, blood cells contained in blood, as well as immature leukocytes and morphologically changed blood cells that appear in the case of blood cell diseases, are distinguished from other blood cells and detected. Various methods for doing this have been proposed.

For example, according to the technique of WO2004 / 001408 (Patent Document 1), blood cells in blood are classified as follows (1) to (3).
(1) First, platelet aggregation is discriminated from leukocytes and erythrocyte ghosts in a two-dimensional scattergram having two axes of the forward scattered light peak and the forward scattered light width.
(2) Next, the leukocytes and erythrocyte ghosts discriminated in (1) are developed into a two-dimensional scattergram having two axes of forward scattered light intensity and fluorescence intensity, and leukocytes and erythrocyte ghosts are discriminated.
(3) Further, the leukocytes discriminated in (2) are expanded into a two-dimensional scattergram having two axes of fluorescence intensity and side scattered light intensity, and leukocytes are converted into lymphocytes, monocytes, granulocytes, myeloblasts. And subdivided into granulocyte immature spheres.

  According to Patent Document 1, myeloblasts can be classified in (3) above, but when a sample containing a small amount of platelet aggregation is measured, platelet aggregation appears in the region of white blood cells and erythrocyte ghosts in (1). And may appear in the area of myeloblasts in (3). For this reason, development of a technique for measuring myeloblasts with higher accuracy is desired.

WO2004 / 001408

The present invention has been made in view of the circumstances as described above, and its purpose is not affected by other components in the sample including platelet aggregation in the measurement of the blood sample by flow cytometry, to provide a TeiSo location measurement that more accurately classifying and counting myeloblast.

  The present inventors have applied two types of scattered light information and fluorescence obtained by applying a flow cytometry to a hematological sample stained stronger than immature leukocytes by damaging the cell membrane of mature leukocytes. Based on the information, bone marrow identified based on one type of scattered light information and fluorescence information by identifying the cell group containing myeloblasts based on the two types of scattered light information and eliminating the influence of platelet aggregation By identifying the cell group containing blasts and distinguishing them from mature leukocytes, it was found that myeloblasts can be measured separately from other blood cells, and the present invention was completed.

That is, the hematological sample measuring apparatus of the present invention is a staining treatment with a fluorescent dye that damages the cell membrane of red blood cells and mature leukocytes contained in the hematological sample, contracts the damaged blood cells, and stains the nucleic acid. the first scattered light information generated by irradiating the excitation light before Symbol fluorochrome processing Gana has been sample, second scattered light based on the different scattered light angle from the first scattered light; sample processing means for Information acquisition means for acquiring information and fluorescence information; and control means for performing analysis for counting myeloblasts based on the first scattered light information and the second scattered light information. It includes myeloblast based on the first scattered light information and process of specifying a first cell group containing myeloblast based on the second scattered light information, the first scattered light information and the fluorescence information processing for specifying a second cell group And the cells contained in and included in the first cell group and the second cell group executes a process of counting as myeloblast.

  The first cell group is a cell group that appears in an appearance candidate region of myeloblast set in a first scattergram having the first scattered light information and the second scattered light information as two axes, The second cell group is preferably a cell group that appears in a myeloblast appearance candidate region set in a second scattergram having the first scattered light information and the fluorescence information as two axes.

  The counting means expands the cells contained in the first cell group and the second cell group into a third scattergram having the fluorescence information and the second scattered light information as two axes, Preferably, it is a means for counting cells appearing in the third scattergram as myeloblasts.

  In the measurement apparatus of the present invention, a display unit that displays at least one of a scattergram in which cells included in the first cell group and cells included in the second cell group appear and a count result of the myeloblasts Further, a light source for irradiating the excitation light may be further provided.

The “young leukocytes” as used in the present invention refers to immature cells that are normally present in the bone marrow and not present in the peripheral blood. For example, it refers to myeloblast, promyelocyte, myelocyte, and rear myelocyte. Promyelocytes, myelospheres, and retromyelocytes may be collectively referred to as immature granulocytes. Furthermore, leukocyte hematopoietic progenitor cells such as myeloid stem cells, neutrophil / macrophage colony forming cells, and eosinophil colony forming cells, which are differentiation stages before blasts, are also included in the scope of the immature leukocytes of the present invention. .
The term “mature leukocytes” as used in the present invention refers to mature lymphocytes, monocytes, granulocytes (neutrophils, eosinophils, basophils).
As used herein, “platelet aggregation” refers to an aggregation of two or more platelets.
“Damage to the cell membrane” in the present invention means that there are pores through which a specific substance can pass through the cell membrane.
The “hematological sample” referred to in the present invention mainly refers to peripheral blood, but in addition to this, a sample containing blood components collected by bone marrow fluid, apheresis, or the like, or leukocyte components such as peritoneal fluid and urine sample A biological sample containing is also a suitable sample.

The hematological sample measuring apparatus of the present invention eliminates the influence of platelet aggregation when discriminating a cell group using fluorescence information obtained by measuring a blood sample by flow cytometry and two types of scattered light information. By appropriately combining the cell groups specified by the first specifying means for specifying the cell group containing myeloblast and the second specifying means for distinguishing the cell group containing myeloblast and the mature leukocyte cell group, respectively. Myeloblasts can be accurately classified and counted. Therefore, myeloblasts can be measured with high accuracy.

It is a scattergram for demonstrating a 1st cell group. It is a scattergram for demonstrating a 2nd cell group. It is a scattergram for demonstrating the cell contained in a 1st cell group and contained in a 2nd cell group. It is a scattergram for demonstrating a 3rd cell group. It is a scattergram for demonstrating a 4th cell group. It is a figure which shows an example of the external appearance of the measuring apparatus of this invention. It is a figure which shows an example of the flow cytometer used for the measuring apparatus of this invention. It is a block diagram which shows an example of a structure of the control part used for the measuring apparatus of this invention. It is a flowchart which shows an example of the information processing employ | adopted with the measuring apparatus of this invention. It is a flowchart which shows the other example of the information processing employ | adopted with the measuring apparatus of this invention. It is a flowchart which shows the other example of the information processing employ | adopted with the measuring apparatus of this invention. It is a flowchart which shows the other example of the information processing employ | adopted with the measuring apparatus of this invention. (A) is a first scattergram obtained by measuring the measurement sample prepared in Example 1, and (b) is a second scattergram obtained by measuring the measurement sample. It is the 3rd scattergram created about Example 1 about the cell contained in both the 1st cell group and the 2nd cell group. (A) is a first scattergram obtained by measuring the measurement sample prepared in Example 2, and (b) is a second scattergram obtained by measuring the measurement sample. It is the 3rd scattergram created about the sample contained in both the 1st cell group and the 2nd cell group about the sample for a measurement of Example 2. FIG.

The method for measuring a hematological sample according to the present invention is a sample in which the cell membrane of red blood cells and mature leukocytes contained in the hematological sample is damaged, blood cells damaged in the cell membrane are contracted, and stained with a fluorescent dye capable of staining nucleic acid. process; first scattered light information generated by irradiating the excitation light before Symbol fluorescent dye to the processing Gana has been sample, the first scattered light and the second scattered light information based on different scattered light angles An acquisition step of acquiring fluorescence information; a step of identifying a cell population containing myeloblasts by distinguishing from other blood cells by eliminating the influence of platelet aggregation using the acquired fluorescence information and two types of scattered light information A counting step of counting the identified myeloblast cell population as myeloblasts;

This will be specifically described below.
[Treatment of hematological samples]
The sample processing step in the measurement method of the present invention is preferably performed by mixing a hematological sample and a processing reagent described below.
The treatment reagent is a reagent capable of staining nucleic acids by damaging the cell membranes of erythrocytes and mature leukocytes contained in a hematological sample, contracting blood cells with damaged cell membranes. Specifically, a surfactant that damages cell membranes of erythrocytes and mature leukocytes contained in a sample and a fluorescent dye that fluorescently stains nucleic acids are included.

  The surfactant used in the present invention damages the cell membrane of erythrocytes and mature leukocytes. Although the mechanism of action is not clear, it is thought that by extracting (pulling out) part of a specific cell membrane lipid component, pores that allow a specific substance to pass through the cell membrane are opened (this is called damage). . The fluorescent dye can enter the inside of the cell damaged by the surfactant and stain the nucleic acid.

  Surfactants also damage immature leukocytes, but require more time for cell damage than erythrocytes and mature leukocytes. For this reason, damaged mature leukocytes are more likely to be stained than uninjured myeloblasts or immature granulocytes within a predetermined time after mixing the hematological sample with the processing reagent. It has become. As a result, myeloblasts and immature granulocytes have less fluorescence intensity than mature leukocytes because they are hardly stained with fluorescent dyes that stain nuclei compared to mature leukocytes that have been damaged and stained in nuclei. .

Examples of the surfactant used in the present invention include polyoxyethylene nonionic surfactants. Specifically, it is a nonionic surfactant represented by R ¹ R ² (CH ₂ CH ₂ O) nH. In the formula, R ¹ is an alkyl group having 9 to 25 carbon atoms, an alkenyl group, or an alkynyl group, and R ² is —O— or —COO— or

であり、ｎは１０〜４０の整数である。

And n is an integer of 10-40.

  Examples of the alkyl group having 9 to 25 carbon atoms include nonyl, decyl, undecyl, dodecyl, tridecyltetradecyl and the like. Examples of the alkenyl group having 9 to 25 carbon atoms include dodecenyl and tetradecenyl. Examples of the alkynyl group having 9 to 25 carbon atoms include dodecinyl, undecynyl, dodecynyl and the like.

  Specific examples include polyoxyethylene (20) lauryl ether, polyoxyethylene (15) oleyl ether, polyoxyethylene (16) oleyl ether and the like.

  The surfactant can be used in the form of an aqueous solution. For example, the concentration of polyoxyethylene nonionic surfactant in water varies depending on the type of surfactant used, but in the case of the polyoxyethylene (16) oleyl ether described above, it is 5 to 50 g / l (preferably 15 to 35 g). / L). If the number of carbon atoms of the hydrophobic group is the same, the polyoxyethylene-based nonionic surfactant has a stronger ability to damage cells as the value of n becomes smaller, and becomes weaker as the value of n becomes larger. Moreover, if the value of n is the same, the force which damages a cell will become strong as carbon number of a hydrophobic group becomes small. Considering this point, the concentration of the necessary surfactant may be appropriately determined by experiment using the above values as a guide.

  The fluorescent dye used in the present invention is a dye that fluorescently stains nucleic acids. For mature leukocytes with damaged cell membranes, the fluorescent dye can pass through the cell membrane and stain the nucleus.

  Specifically, ethidium bromide, propidium iodide, ethidium-acridine heterodimer, ethidium azide, ethidium homodimer-1, ethidium homodimer-2, ethidium monoazide sold by Molecular Probes, TOTO-1, TO- PRO-1, TOTO-3, TO-PRO-3, etc. are mentioned. Furthermore, a dye represented by the following formula (1) can be used as a suitable dye when using He—Ne, a red semiconductor laser, or the like as a light source.

式中、Ｒ^３は水素原子、低級アルキル基又は低級アルコキシ基、Ｒ^４は水素原子、アシル基、又は低級アルキル基、Ｒ^５は水素原子又は置換されていてもよい低級アルキル基、Ｒ^６は水素原子又は低級アルキル基、Ｒ^７は水素原子、低級アルキル基又は低級アルコキシ基、及びＺは硫黄原子、酸素原子又は低級アルキル基で置換された炭素原子、ｍは１又は２、Ｘはアニオンである。

In the formula, R ³ is a hydrogen atom, a lower alkyl group or a lower alkoxy group, R ⁴ is a hydrogen atom, an acyl group, or a lower alkyl group, R ⁵ is a hydrogen atom or an optionally substituted lower alkyl group, and R ⁶ is A hydrogen atom or a lower alkyl group, R ⁷ is a hydrogen atom, a lower alkyl group or a lower alkoxy group, and Z is a carbon atom substituted with a sulfur atom, an oxygen atom or a lower alkyl group, m is 1 or 2, and X is an anion. is there.

Lower alkyl in R ³ , R ⁴ , R ⁵ , R ⁶ , and R ⁷ means a linear or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, butyl, isobutyl, Examples include sec-butyl, ter-butyl, pentyl, and hexyl groups. Among them, a methyl group and an ethyl group are preferable.
The lower alkoxy group for R ³ and R ⁷ means an alkoxy group having 1 to 6 carbon atoms, and examples thereof include methoxy, ethoxy, propoxy, etc. Among them, a methoxy group and an ethoxy group are preferable. R ³ and R ⁷ are preferably hydrogen atoms.
The acyl group in R ⁴ is preferably an acyl group derived from an aliphatic carboxylic acid, and examples thereof include acetyl and propionyl. Among them, an acetyl group is preferable.
The lower alkyl group which may be substituted in R ⁵ means a lower alkyl group which may be substituted with 1 to 3 hydroxyl groups, halogen atoms (fluorine, chlorine, bromine or iodine), etc. A methyl group and an ethyl group substituted with a single hydroxyl group are preferred.

The lower alkyl group for Z is preferably a sulfur atom as Z.
Anions in X ⁻ are halogen ions (fluorine, chlorine, bromine or iodine ions), boron halide ions (BF ₄ ⁻ , BCl ₄ ⁻ , BBr ₄ ⁻ etc.), phosphorus compound ions, halogen oxygenate ions, fluorosulfate ions And methylsulfuric acid ion, and a tetraphenylboron compound ion having a halogen or an alkyl group having a halogen in the aromatic ring as a substituent. Of these, bromine ion or BF ₄ ⁻ is preferable.

  As specific examples of the dye of the above formula (1), the following dye A, dye B, and dye C are preferable.

  The dye concentration can be appropriately determined according to the dye used. Preferably, the concentration in the reagent is 0.01 to 500 ppm, more preferably 0.1 to 200 ppm.

  The above-mentioned surfactant damages the cell membrane, and a part of the cell is discharged out of the cell to cause cell contraction, or due to a change in the surface state of the cell membrane, cell contraction occurs. In order to make blood cells, especially red blood cells, a ghost population that does not provide useful scattered light information and fluorescence information, it is preferable to include a solubilizer to sufficiently contract damaged cells.

  Specifically, the solubilizer is a sarcosine derivative represented by the following formula (2) or a salt thereof;

（式中、Ｒ^１０は炭素数１０〜２２のアルキル基、ｐは１〜５の整数である。）
下記（３）式で表されるコール酸誘導体；

(In the formula, R ¹⁰ is an alkyl group having 10 to 22 carbon atoms, and p is an integer of 1 to 5.)
A cholic acid derivative represented by the following formula (3):

（式中、Ｒ^１１は水素原子又は水酸基）
及び下記（４）式

(Wherein R ¹¹ is a hydrogen atom or a hydroxyl group)
And the following formula (4)

（式中、ｑは５〜７）
で表されるメチルグルカンアミドから選択される１又はそれ以上を用いることができる。

(Wherein q is 5-7)
One or more selected from methylglucanamide represented by the formula:

  Examples of the alkyl group having 10 to 22 carbon atoms include decyl, dodecyl, tetradecyl, oleyl and the like.

  Specifically, sodium N-lauroyl sarcosinate, sodium lauroylmethyl β-alanine, lauroyl sarcosine, CHAPS (3- [3-cholamidopropyl) dimethylammonio] -1-propanesulfonate), CHAPSO (3- [3 -Cholamidopropyl) dimethylammonio] -2-hydroxy-1-propanesulfonate), MEGA8 (octanoyl-N-methylglucamide), MEGA9 (nonanoyl-N-methylglucamide), MEGA10 (decanoyl-N-methylgluca) Mid) and the like.

  The concentration of the solubilizer is 0.2 to 2.0 g / l for sarcosine acid derivatives or salts thereof, 0.1 to 0.5 g / l for cholic acid derivatives, and 1.0 to 8.0 g for methyl glucanamide. / L is preferred.

  In addition to the above, n-octyl β-glucoside, sucrose monocaprate, N-formylmethyl leucylalanine, etc. may be used as the solubilizer, and they may be used at a concentration of 0.01 to 50.0 g / l. preferable.

  Further, it preferably contains a pH adjusting agent and a buffer for adjusting the pH of the reagent, and further preferably contains an osmotic pressure adjusting agent if necessary.

  As the buffer, Good buffer such as HEPES, phosphate buffer, or the like is used. Sodium hydroxide etc. are used as a pH regulator. As the osmotic pressure regulator, sugar, amino acid, organic solvent, sodium chloride and the like are used. As the sugar, glucose, xylitol mannitol, arabinose, ribitol and the like can be used. As the amino acid, alanine, proline, glycine, valine and the like can be used. As the organic solvent, ethylene glycol, glycerin, or the like can be used. The concentration of the osmotic pressure regulator in the reagent is appropriately adjusted depending on the molecular weight. For example, when xylitol is used, it is preferably 10 to 75 g / l, when glycerin is used, it is preferably 5 to 45 g / l, and when glycine is used. Is preferably 5 to 45 g / l.

  The treatment reagent having the above composition preferably has a pH of 5.0 to 9.0 and an osmotic pressure of 150 to 600 mOsm / kg.

  The treatment reagent may be a one-component reagent containing a surfactant, a dye, and other components, or a staining solution containing a fluorescent dye and a solution containing the above-described surfactant (hemolytic agent). Can be stored in separate containers, and a reagent kit provided with these can be used. In this case, in order to improve the storage stability of the dye, it is preferable to use a water-soluble organic solvent such as ethylene glycol as the solvent of the fluorescent dye.

[Preparation of sample for measurement]
A sample for measurement can be prepared by mixing a solution containing the processing reagent and a hematological sample. When using the above-described reagent kit, first, a solution containing a surfactant (hemolytic agent) and a hematological sample may be mixed, and then a staining solution may be mixed to obtain a measurement sample.

  In the mixing of the hematological sample and the processing reagent, the ratio of sample: processing reagent is preferably 1:10 to 1: 1000, the reaction temperature is preferably 20 to 40 ° C., and the reaction time is 3 seconds to 5 minutes. More preferably, it is 4 seconds to 1 minute.

  In the measurement sample prepared in this way, red blood cells and mature white blood cells are contracted and reduced in size. In particular, since red blood cells do not have nuclei, hemolysis and cell contraction progress due to cell membrane damage, and they are not stained with fluorescent dyes. Therefore, all of forward scattered light, side scattered light, and fluorescent light are reduced and treated as a ghost population. Can do.

  On the other hand, mature leukocytes are contracted by reacting a sample and a reagent for a predetermined time by damaging the cell membrane, but the nuclei are not substantially contracted and thus are not as small as red blood cells. In addition, nuclei are stained because the fluorescent dye can penetrate the damaged membrane.

  Because immature leukocytes are more resistant to hemolytic agents than mature leukocytes and erythrocytes, it takes time to damage the cell membrane. Accordingly, cell contraction does not substantially occur within a predetermined reaction time, and since the fluorescent dye cannot permeate, the nucleus is hardly stained.

  For individual platelet cells, the treatment reagent takes time to damage the membrane like immature leukocytes, and the dye does not enter the platelets and stain the platelets themselves. In the case of platelet aggregates, The dye is physically adsorbed around the collection and dyed.

[Obtaining scattered light information and fluorescence information]
The prepared measurement sample is measured with a flow cytometer, and scattered light information and fluorescence information such as cells and platelets contained in the sample are acquired.

  Information acquisition is preferably performed by introducing a measurement sample into a flow cell of a flow cytometer and irradiating the sample flowing in the flow cell with excitation light capable of exciting the fluorescent dye. Thereby, scattered light information and fluorescence information emitted from cells passing through the flow cell can be acquired.

The irradiation light includes light having a wavelength that can excite the fluorescent dye to be used. Depending on the wavelength of the light of the light source provided in the flow cytometer to be used, a fluorescent dye that can be excited by the light may be selected.
The scattered light information acquires two types of scattered light having different angles. Specifically, a combination of forward scattered light and side scattered light is preferably used.

  Here, the forward scattered light is considered to be information reflecting the size of the cell. In other words, the larger the cell, the greater the forward scattered light. Side scattered light is scattered light having an angle of 80 to 100 degrees, preferably 85 to 95 degrees, with respect to forward scattered light. From the side scattered light, it is possible to obtain internal cell information, particularly information on the nucleus. The side scattered light tends to increase when it contains granules or the shape of the nucleus is irregular.

  Within a predetermined reaction time, the fluorescent dye hardly penetrates into the inside of the platelet, so that the platelet itself is hardly stained. However, since the fluorescent dye binds to the periphery of the platelet aggregate and to the portion where the platelets are bonded, the fluorescence intensity increases as the aggregate increases in the measurement sample. On the other hand, when the platelet aggregation is small and the aggregate is small, the side scattered light intensity is small and the fluorescent dye adhering is small. As a result, the fluorescence intensity is also small.

[Identification of cell group and myeloblast count]
Using the obtained scattered light information and fluorescence information, a target cell group is specified, and myeloblasts are counted. The measurement method of the present invention can be classified into the following first measurement method to fourth measurement method from the viewpoint of the specific process. Hereinafter, it demonstrates in order.

(1) First Measurement Method In the first measurement method, a first cell group including myeloblasts is specified based on the acquired first scattered light information and second scattered light information (first specifying step). Based on the acquired first scattered light information and the fluorescence information, a second cell group including myeloblasts is specified (second specifying step), included in the first cell group and included in the second cell group Cells are counted as myeloblasts. Any order may be sufficient as the order of a 1st specific process and a 2nd specific process.

(1-1) First Cell Group The first cell group is specified based on the acquired two types of scattered light information, preferably forward scattered light intensity and side scattered light intensity. The first cell group is preferably specified by setting a region where myeloblasts appear to appear in a scattergram (first scattergram) having the two types of scattered light information as two axes. In addition, since the degree and size of myeloblast staining differs depending on the specimen, it is preferable to set the region where the first cell group appears for each specimen.

As a specific setting method of the region where the first cell group appears, first, when a cell population is found at a position where myeloblasts appear to appear in a scattergram having two types of scattered light information as two axes, Identify the center of this population. The region from the center of the myeloblast cell population to the appearance region of other cell populations to the portion where the cells of the myeloblast cell population appear is determined as the boundary of the appearance region of the first cell group. be able to. Similarly, if a cell population is found at a position where other cell populations (immature granulocytes, granulocytes, lymphocytes, monocytes) appear, specify the center of each population and select the region of appearance. Identify. These areas are the dyes used,
Depending on the concentration, regions may be set in advance from data accumulated for myeloblasts of various sizes.

  In the scattergram having the measurement sample used in the present invention as a biaxial axis with forward scattered light intensity (first scattered light information) on the vertical axis and side scattered light intensity (second scattered light information) on the horizontal axis, When an area where each cell appears to appear is generally set, it is as shown in FIG. In FIG. 1, “Blast” is a myeloblast appearance region, “IG” is an immature granulocyte appearance region, “Gran” is a granulocyte appearance region, “Ly” is a lymphocyte appearance region, and “Mo” is a single region. This is the appearance area of the sphere.

  Myeloblasts appear in a relatively left region in the scattergram because the side scattered light intensity is weak. On the other hand, granulocytes and immature granulocytes appear on the right side with relatively large side scattered light due to the distorted form of their nuclei. Will appear. Therefore, the region indicated by the alternate long and short dash line surrounding the blast portion may be set as the appearance region of the first cell group.

  Platelet aggregation has a wide range of aggregation methods, so that the side scattered light intensity ranges from small to large, and the size of aggregates varies from several to several tens. The strength ranges from small to large. However, since there is a correlation between the size of the agglomerate and the annoyance, it appears in the area from the lower left to the upper right (area surrounded by a dotted line) in the scattergram shown in FIG. It does not overlap with (appearance area of the first cell group).

  According to FIG. 1, since the first cell group is distinguished from platelet aggregation and other blood cell components, it is considered possible to count the first cell group as myeloblasts. However, depending on the sample, lymphocytes having a large size may be included, and although rare, a part of the lymphocyte appearance region may overlap the appearance region of the first cell group.

(1-2) Second Cell Group The second cell group is specified based on the acquired first scattered light information and fluorescence information, preferably, forward scattered light information and fluorescence information. The second cell group is a cell population included in an area where myeloblasts appear to appear in a scattergram (second scattergram) having two axes of forward scattered light intensity and fluorescence intensity.

  Myeloblasts and immature granulocytes do not undergo nuclear staining within a predetermined reaction time and thus do not undergo nuclear staining and appear in the left region where the fluorescence intensity is low. Therefore, immature leukocytes may also appear in areas where myeloblasts are expected to appear. On the other hand, granulocytes, lymphocytes, and monocytes are stained in the nucleus due to membrane damage caused by the treatment reagent in a predetermined reaction time, and thus appear in the right region with high fluorescence intensity. It can be clearly distinguished from a population of immature leukocytes that are not substantially nuclearly stained. That is, mature leukocytes do not substantially appear in the appearance region of immature leukocytes including myeloblasts.

Therefore, as a specific method for specifying the appearance region of the second cell group, first, when a cell population is recognized at a position where a myeloblast appears in the scattergram, the center of this population is specified. From the center of the myeloblast cell population to the appearance region of the cell population of the mature leukocyte cell population to the portion where the cells of the myeloblast cell population appear, the appearance region of the second cell group It can be determined as a boundary. Similarly, if a cell population is found at a position where other cell populations (immature granulocytes, granulocytes, lymphocytes, monocytes) appear, specify the center of each population and select the region of appearance. Identify. These regions may be set in advance from data accumulated for myeloblasts of various sizes depending on the dye and concentration used.

  Specifically, as shown in FIG. 2, in the scattergram with the fluorescence intensity as the horizontal axis and the forward scattered light intensity as the vertical axis, the second cell group is surrounded by a one-dot chain line in the left region where the fluorescence intensity is low. It becomes a group included in the area. In FIG. 2, “Blast” is the myeloblast appearance region, “IG” is the immature granulocyte appearance region, “Gran” is the granulocyte appearance region, “Ly” is the lymphocyte appearance region, and “Mo” is the single region. It is a sphere appearance area.

  Note that the staining of platelet aggregation appears in the left region because it is physically adsorbed. In addition, depending on the degree of aggregation, there may be a small to large size than myeloblasts. Therefore, as shown in FIG. 2, a region extending in a longitudinal direction from a small forward scattered light intensity to a large one. Appears on.

(1-3) Counting of myeloblasts Cells included in the first cell group specified as described above and included in the second cell group are counted as myeloblasts.

  Lymphocytes that may be included in the first cell group are not included in the second cell group. On the other hand, platelet aggregation and immature leukocytes that may be contained in the second cell group are not contained in the first cell group. Therefore, it can be said that the cells contained in the first cell group and contained in the second cell group do not contain lymphocytes, platelet aggregation, and immature leukocytes, but are substantially only myeloblasts. Therefore, it is possible to accurately count myeloblasts by counting the cells included in the first cell group and included in the second cell group as myeloblasts.

  The cells included in the first cell group and included in the second cell group may be developed in a scattergram (third scattergram) having fluorescence information and second scattered light information as two axes. . Cells appearing in the third scattergram are substantially a population of myeloblasts only.

  The first scattered light information is preferably forward scattered light intensity, and the second scattered light information is preferably side scattered light intensity. When the cells included in the first cell group and the second cell group are expanded into a scattergram (third scattergram) having two axes of fluorescence intensity and side scattered light intensity, for example, as shown in FIG. A scattergram is obtained. In this scattergram, cells contained in the first cell group and contained in the second cell group, that is, substantially only myeloblasts have appeared. Can also be counted.

(2) Second measurement method In the first measurement method and the second measurement method, the first specifying step and the second specifying step are individually performed to specify the first cell group and the second cell group, respectively. The first cell group (or the second cell group) is specified first, and then the second cell group (or the first cell group) is selected from the first cell group (or the second cell group) specified above. It may be specified.
That is, the second measurement method specifies a second cell group including myeloblasts based on the acquired first scattered light information and fluorescence information (second specifying step), and then specifies the specified second cell group. Based on the first scattered light information and the second scattered light information, the first cell group is identified from the second cell group (if the second measurement method is specifically referred to, this identification is performed. The step is referred to as “first ′ specifying step”, the first cell group specified in the first ′ specifying step is referred to as “first ′ cell group”), and the first ′ cell group is counted as myeloblast. Or based on the acquired 1st scattered light information and 2nd scattered light information, the 1st cell group containing a myeloblast is specified (1st specific process), and then the 1st scattered light information of the specified 1st cell group was identified. And specifying the second cell group from the first cell group based on the fluorescence information (when specifically referring to the second measurement method, this specifying step is referred to as “second 'specifying step”, The second cell group specified in the second ′ specifying step is referred to as “second ′ cell group”), and this second ′ cell group is counted as myeloblast.

  The first specifying step and the first cell group specified there, the second specifying step and the second cell group specified there are specified based on the scattered light information and fluorescence information acquired in the acquiring step, respectively, Since the method is the same as the first measurement method, description thereof is omitted.

(2-1) Identification of 2 ′ cell group and counting of myeloblasts The 2 ′ identification step includes the first scattered light information (preferably forward scattered light intensity) and fluorescence information of the first cell group previously identified. Based on (preferably fluorescence intensity), a population containing myeloblasts is specified from the first cell group (specification of the second ′ cell population). The 2 ′ cell group specified in this way corresponds to the cells included in the first cell group and the second cell group in the first measurement method and the second measurement method.

The specification of the 2 ′ cell population is specifically performed as follows.
First, a scattergram (first scattergram) having the first scattered light information and the second scattered light information as axes is created, and all the formed components (cells, platelets, etc.) are developed on the scattergram. A candidate area for myeloblasts is set in the first scattergram, and a first cell group appearing in this area is specified. Next, a scattergram (second 'scattergram) having two axes of the first scattered light information and the fluorescence information is created, and only the first cell group is developed on the scattergram. In the 2 ′ scattergram, a cell population included in a region where myeloblasts are considered to appear is the 2 ′ cell group. In the 2 ′ scattergram with the first scattered light information and the fluorescence information as two axes, mature leukocytes and immature leukocytes are clearly distinguished, even if lymphocytes are included in the first cell group. The 2 ′ cell group developed in the 2 ′ scattergram does not contain lymphocytes. That is, the 2 ′ cell group is a population of myeloblasts substantially free of other components such as platelet aggregation and lymphocytes. Therefore, the cells contained in the 2 ′ cell group may be counted as myeloblasts.

(2-2) First 'cell group identification and myeloblast counting The first' identification step identifies the second cell group by the second identification step, and the first scatter of the identified second cell group. Based on light information (preferably forward scattered light intensity) and second scattered light information (preferably side scattered light intensity), a group including myeloblasts is identified from the second cell group (first 'Identification of cell population). The first ′ cell group specified in this way corresponds to the cells included in the first cell group and the second cell group in the first measurement method and the second measurement method.

The identification of the first 'cell population is specifically performed as follows.
First, the acquired first scattered light information (preferably forward scattered light intensity) and fluorescent information (preferably fluorescent intensity) are used, and a scattergram (second scattergram) having the first scattered light information and fluorescent information as two axes is obtained. Create and expand all tangible components (cells, platelets, etc.) on this scattergram. In this second scattergram, a candidate region for the second cell group including myeloblasts is identified. Next, a scattergram (first 'scattergram) having two axes of the first scattered light information and the second scattered light information is created, and only the second cell group specified above is developed in this scattergram. A cell population included in a region where myeloblasts appear to appear in the first 'scattergram is the first' cell group. In the 1 ′ scattergram with the first scattered light information and the second scattered light information as two axes, immature leukocytes and platelet aggregation appear in a region that can be clearly distinguished from the region in which myeloblasts appear. The first 'cell group is substantially free of other components such as platelet aggregation, lymphocytes, and immature leukocytes. Therefore, the cells contained in the first 'cell group may be counted as myeloblasts.

(3) Third measurement method In the first and second measurement methods, any specification is required for specifying the first cell population (or first 'cell population) and the second cell population (or second' cell population). Also in the process, after specifying each cell population individually based on two types of information, the cell population included in the first cell population and included in the second cell population is specified, and this is used as myeloblast. The hematological sample measurement method of the present invention uses the first scattered light information, the second scattered light information, and the fluorescence information to obtain a single cell population and a single second cell population. The cells specified in the process and included in both the first cell population and the second cell population may be determined and counted as myeloblasts.

  That is, in the third measurement method, the first cell group including myeloblasts is specified based on the acquired first scattered light information and second scattered light information, and the acquired first scattered light information and fluorescence information are included in the acquired first scattered light information and fluorescent information. Based on this, the second cell group containing myeloblasts is identified, and the cells contained in the first cell group and contained in the second cell group are counted as myeloblasts.

  Specifically, the first scattered light information (preferably the forward scattered light intensity) and the first scattered light information (preferably the forward scattered light intensity) are developed into a three-dimensional scattergram having three axes of the first scattered light information, the second scattered light information, and the fluorescence information. The first cell group including myeloblasts is identified based on the second scattered light information (preferably side scattered light intensity), and the first scattered light information (preferably forward scattered light intensity) and fluorescence information (preferably Based on the fluorescence intensity), the second cell group containing myeloblasts is identified. The identification method of the first cell group and the identification method of the second cell group at this time can be performed in the same manner as in the first measurement method. In short, in the three-dimensional scattergram, the first cell group and the second cell group can be specified at the same time, and further, the cells included in the first cell group and the second cell group can be specified. Can do. As described in the first measurement method, the cells contained in the first cell group and contained in the second cell group substantially do not contain other cell components such as platelet aggregation and lymphocytes. Therefore, if the cells contained in the first cell group and the second cell group are counted as myeloblasts in the three-dimensional scattergram, the myeloblasts can be counted with high accuracy.

(4) Fourth measurement method The fourth measurement method is a cell group specified based on the acquired first scattered light information and fluorescence information, instead of the second cell group containing myeloblasts, other than the ghost population. (In the measurement sample used in the present invention, since red blood cells are a ghost population due to cell contraction, the third cell group containing substantially all white blood cells) is specified. .

  That is, in the fourth measurement method, the first cell group including myeloblasts is specified based on the acquired first scattered light information and second scattered light information (first specifying step), and the acquired first scattered light is obtained. Based on the light information and the fluorescence information, a third cell group including all leukocytes is identified (third identification step), and based on the second scattered light information and the fluorescence information of the third cell group, the third cell group A fourth cell group that substantially does not contain at least mature leukocytes is identified from among (4th identifying step), and cells that are included in the first cell group and included in the fourth cell group are counted.

Since the 1st specific process and the 1st cell group are the same as that of the 1st measuring method, explanation is omitted.
(4-1) Third identification step and third cell group The third cell group appears in a region excluding the region where the erythrocyte ghost population appears in a scattergram having two axes of forward scattered light intensity and fluorescence intensity. A population of cells, ie a population of substantially total white blood cells. Specifically, when a scattergram having a horizontal axis of fluorescence intensity and a vertical axis of forward scattered light intensity is drawn, as shown in FIG. 4, a cell population appearing in a region surrounded by an alternate long and short dash line is a third one. It becomes a cell group. Note that the appearance area of the third cell group includes platelet aggregation as shown in FIG.

(4-2) Fourth identification step and fourth cell group The fourth cell group is identified based on the second scattered light information and fluorescence information, preferably side scattered light information and fluorescence information of the third cell group. . When the third cell group is expanded in a scattergram with the fluorescence intensity and the side scattered light intensity as two axes, the region where mature leukocytes appear and the region where immature leukocytes appear are clearly distinguished. If the region considered to contain myeloblasts in the scattergram with the intensity and side scattered light intensity as two axes is identified, the cell population containing immature leukocytes, and the appearance region of the population containing myeloblasts Can be specified. Here, the specification of the myeloblast candidate region is preferably performed for each specimen, similarly to the specification of the first cell group and the second cell group. Moreover, according to the pigment | dye to be used and a density | concentration, you may preset from the data accumulated about the myeloblast of various sizes, and a mature leukocyte.

  When the third cell group is expanded in a scattergram in which the lateral scattered light intensity is the horizontal axis and the fluorescence intensity is the vertical axis, mature leukocytes (lymphocytes, monocytes, and granulocytes), as shown in FIG. Since the nucleus is stained, it appears upward and can be clearly distinguished from immature leukocytes that are not substantially stained. Mature leukocytes appear as a lymphocyte population (Ly), a monocyte population (Mo), and a granulocyte population (Gran) in order from the left depending on the morphology of the nucleus. Platelet aggregation appears downward, from left to right. Therefore, in the left region where the side scattered light intensity is low, the cell population in the region surrounded by the alternate long and short dash line including myeloblasts is specified as the fourth cell group. do it. Since myeloblasts and immature granulocytes have different nuclei morphology and complexity, it is possible to distinguish them from each other by the intensity of the side scattered light. When the targeting is difficult, a cell population included in an appearance region of immature granulocytes including both myeloblasts and immature granulocytes may be used as the fourth cell group.

(4-3) Identification and Counting of Myeloblasts The cells contained in the first cell group and the fourth cell group identified as described above are counted. Since the first cell group does not contain platelet aggregation and the fourth cell group does not contain mature leukocytes, the cells contained in the first cell group and contained in the fourth cell group are substantially A population of myeloblasts or immature leukocytes that does not contain platelet aggregation or mature leukocytes. That is, even if the first cell group contains lymphocytes, the cells contained in the first cell group and contained in the fourth cell group are substantially free of bone marrow because the lymphocytes are excluded. Blasts or immature leukocytes can be counted with high accuracy.

[Discrimination method]
How to discriminate between myeloblast and platelet aggregation contained in a hematological sample of the present invention, sample processing steps in the measurement process of the present invention; forward scattering caused by irradiating light to the processing Gana has been sample Obtaining light information and side scattered light information; and identifying a first cell group containing myeloblasts based on the forward scattered light information and the side scattered light information, It is a method for discriminating between a cell population containing spheres and platelet aggregation.

  As described above, in the scattergram having the forward scattered light information and the side scattered light information as two axes, when an area where myeloblasts are expected to appear is identified, the area where platelet aggregation is expected to appear is clear. Therefore, it is possible to discriminate between myeloblasts and platelet aggregation contained in the hematological sample.

[Measuring equipment for hematological samples]
The measurement apparatus of the present invention is a sample processing means for dying red blood cells and mature white blood cells contained in a hematological sample, contracting blood cells damaged by the cell membrane, and staining with a fluorescent dye capable of staining nucleic acid; a first scattered light information generated by irradiating the excitation light before Symbol fluorochrome Gana has been sample, the first scattered light and the second scattered light information based on different scattered light angles, and fluorescence information Acquisition means for acquiring; first specifying means for specifying a first cell group containing myeloblasts based on the first scattered light information and the second scattered light information; based on the first scattered light information and the fluorescence information And a second specifying means for specifying a second cell group containing myeloblasts; and a counting means for counting the cells contained in the first cell group and contained in the second cell group as myeloblasts.

The measuring device of the present invention has an appearance as shown in FIG. 6, for example.
The apparatus illustrated in FIG. 6 includes a measurement unit 1, an analysis unit 2, and a signal cable 3 that connects the analysis unit 2 and the measurement unit 1. The measurement unit 1 includes the sample processing unit and the acquisition unit of the apparatus of the present invention, and the analysis unit 2 includes the first specifying unit, the second specifying unit, and the counting unit of the present invention.
The measurement unit 1 includes a liquid crystal touch panel 10 for an operator to input various settings, a start switch 11 for starting a measurement operation, and a probe 12 for aspirating a specimen. Further, a flow cytometer as shown in FIG. 7 is mounted inside the measurement unit 1. The analysis unit 2 includes a control unit 6 that controls processing of information transmitted from the measurement unit 1, an operation of the measurement unit 1, an output unit 7 that displays various measurement results, and an operator who selects sample information. And a keyboard 8 for inputting.

Next, the flow cytometer shown in FIG. 7 will be described.
A beam emitted from a light source (for example, a red semiconductor laser: wavelength 633 nm) 21 irradiates the orifice portion of the sheath flow cell 23 via a collimator lens 22. Forward scattered light emitted from blood cells discharged from the nozzle 20 and passing through the orifice part is incident on a forward scattered light detector (photodiode) 26 via a condenser lens 24 and a pinhole plate 25. On the other hand, the side scattered light emitted from the blood cells passing through the orifice part enters the side scattered light detector (photomultiplier tube) 29 via the condenser lens 27 and the dichroic mirror 28. Further, the side fluorescence emitted from the blood cells passing through the orifice part enters the side fluorescence detector (photomultiplier tube) 31 through the condenser lens 27, the dichroic mirror 28, the filter 28 ', and the pinhole plate 30. To do. The forward scattered light signal output from the forward scattered light detector 26, the side scattered light signal output from the side scattered light detector 29, and the side fluorescent signal output from the side fluorescent detector 31 are as follows. Are amplified by the amplifiers 32, 33 and 34, respectively, and input to the control unit 6.

  The light source 21 emits light that can excite the dye used for processing the sample to the orifice portion of the flow cell into which the prepared measurement sample is introduced, and is used as a fluorescent dye that stains blood cells in the sample. The one that matches is selected. Therefore, depending on the type of fluorescent dye used, for example, an argon laser, a He—Ne laser, a blue semiconductor laser, or the like may be used in addition to the red semiconductor laser.

  FIG. 8 is a block diagram illustrating a configuration of the control unit 6. The control unit 6 mainly includes a CPU 6a, a ROM 6b, a RAM 6c, a hard disk 6d, an input / output interface 6e, an image output interface 6f, and a communication interface 6g. The CPU 6a, the ROM 6b, the RAM 6c, and the hard disk 6d. The input / output interface 6e, the output interface 6f, and the communication interface 6g are connected by a bus 6h so that data communication is possible.

  The CPU 6a can execute computer programs stored in the ROM 6b and the hard disk 6d and computer programs read out to the RAM 6c. Therefore, based on the forward scattered light signal, the side scattered light signal, and the fluorescence signal input from the measurement unit 1, specifically, the flow cytometer, the set program is processed, and the first cell group, A cell group, such as the second cell group, is identified and myeloblasts are counted.

  The ROM 6b stores a computer program to be executed by the CPU 6a, data used for executing the computer program, and the like. The RAM 6c is used for reading a computer program stored in the ROM 6b and the hard disk 6d and for a work area of the CPU 6a when executing the computer program. The hard disk 6d stores a computer program to be executed by the CPU 6a and data used for executing the computer program. This computer program functions to analyze optical information and output an analysis result.

  A keyboard 8 is connected to the input / output interface 6e. The keyboard 8 serving as an input unit is provided for operations on the output screen. The output interface 6f is connected to the output unit 7 composed of a liquid crystal display. The output unit 7 is provided for outputting and displaying the analysis result obtained by the control unit 6. The communication interface 6g is connected to the measuring unit 1 and fulfills a function for receiving optical information.

Next, an embodiment of information processing in the control unit 6 will be described.
FIG. 9 is a flowchart showing information processing corresponding to the first measurement method of the present invention. When the control unit 6 employs the second measurement method, first, the forward scattered light signal, the side scattered light signal, and the fluorescence signal detected by the measuring unit 1 are received via the signal cable 3 (step S1). The control unit 6 analyzes these signals and calculates the respective signal strengths (step S2). Next, using the forward scattered light intensity and the side scattered light intensity of the formed component (cells, platelets, etc.) in the sample, a first scattergram with the forward scattered light intensity and the side scattered light intensity as two axes is created. (Step S3). In the first scattergram, a myeloblast candidate region where myeloblasts are considered to appear is set, and a first cell group included in this region is specified (step S4). Further, a second scattergram having two axes of the forward scattered light intensity and the fluorescence intensity is created using the forward scattered light intensity and the fluorescence intensity of the formed component in the sample (step S5). In the second scattergram, a myeloblast candidate region where myeloblast is considered to appear is set, and a second cell group included in this region is specified (step S6). Next, using the fluorescence intensity and side scattered light intensity of the cells contained in the first cell group and in the second cell group, a third scattergram with the fluorescence intensity and the side scattered light intensity as two axes is created. (Step S7). Cells appearing in the third scattergram (cells included in the first cell group and also included in the second cell group) are counted as myeloblasts (step S8), and the counting result and the third scattergram Is output to the output unit 7 (step S9).

  FIG. 10 is a flowchart showing information processing corresponding to the method of first specifying the first cell group in the second measurement method of the present invention. When the control unit 6 employs such a second measurement method, first, the forward scattered light signal, the side scattered light signal, and the fluorescence signal detected by the measurement unit 1 are received via the signal cable 3. (Step S1). The control unit 6 analyzes these signals and calculates the respective signal strengths (step S2). Next, using the forward scattered light intensity and the side scattered light intensity of the formed component (cells, platelets, etc.) in the sample, a first scattergram with the forward scattered light intensity and the side scattered light intensity as two axes is created. (Step S3). In the first scattergram, a myeloblast candidate region where myeloblasts are considered to appear is set, and a first cell group included in this region is specified (step S4). Further, using the forward scattered light intensity and the fluorescence intensity of the first cell group, a scattergram (second 'scattergram) having the forward scattered light intensity and the fluorescence intensity as two axes is created (step S5). In the second 'scattergram, a myeloblast candidate region where myeloblasts are considered to appear is set, and a second' cell group included in this candidate region is specified (step S6). The second 'cell group is counted as myeloblasts (step S7), and the counting result and the second' scattergram are output to the output unit 7 (step S8).

  FIG. 11 is a flowchart showing information processing corresponding to a method of first specifying the second cell group in the second measurement method of the present invention. When the control unit 6 employs such a second measurement method, first, the forward scattered light signal, the side scattered light signal, and the fluorescence signal detected by the measurement unit 1 are received via the signal cable 3. (Step S1). The control unit 6 analyzes these signals and calculates the respective signal strengths (step S2). Next, a second scattergram having two axes of the forward scattered light intensity and the fluorescence intensity is created using the forward scattered light intensity and the fluorescence intensity of the formed component (cell, platelet, etc.) in the sample (step S3). In the second scattergram, a myeloblast candidate region in which myeloblasts appear to appear is set, and a second cell group included in this region is specified (step S4). Next, using the forward scattered light intensity and the side scattered light intensity of the second cell group, a scattergram (first 'scattergram) with the forward scattered light intensity and the side scattered light intensity as two axes is created (step 1). S5). In the 1 'scattergram, a myeloblast candidate region where myeloblasts are considered to appear is set, and a first' cell group included in this candidate region is specified (step S6). The first 'cell group is counted as myeloblasts (step S7), and the counting result and the first' scattergram are output to the output unit 7 (step S8).

  FIG. 12 is a flowchart showing information processing corresponding to the third measurement method of the present invention. When the control unit 6 employs such a third measurement method, first, the forward scattered light signal, the side scattered light signal, and the fluorescence signal detected by the measurement unit 1 are received via the signal cable 3. (Step S1). The control unit 6 analyzes these signals and calculates the respective signal strengths (step S2). Next, a three-dimensional scattergram having three axes of forward scattered light intensity, side scattered light intensity, and fluorescence intensity of the formed component (cells, platelets, etc.) in the sample is created (step S3). In the three-dimensional scattergram, the first cell group based on the forward scattered light intensity and the side scattered light intensity and the second cell group based on the forward scattered light intensity and the fluorescence intensity are specified (step S4). In the three-dimensional scattergram, a myeloblast region where cells included in the first cell group and also included in the second cell group appear is set, and the cells appearing in this region are counted as myeloblasts (step S5). The myeloblast count result and the three-dimensional scattergram are output to the output unit 7 (step S8).

  In the apparatus of the above embodiment, the control unit 6 outputs and displays the myeloblast counting result and the scattergram used for the counting on the display unit of the output unit 7, but only one of them is output. May be. When outputting a scattergram, not only the scattergram finally used for counting myeloblasts, but also all of the created scattergrams may be output.

  The measurement apparatus according to the above embodiment employs the first to third measurement methods of the present invention, but when the fourth measurement method is employed, the acquired fluorescence information and the second scattering are used. And a third specifying means for specifying a fourth cell group not containing at least mature leukocytes based on the optical information, wherein the counting means is included in the first cell group and included in the second cell group; It is preferable that the cell included in the cell group specified by the third specifying means is a means for counting as myeloblasts.

  For an apparatus that employs the fourth measurement method, specifically, it is only necessary to change the information processing in the control unit 6 of the above embodiment. However, the second specifying means specifies a group of all white blood cells including myeloblasts (corresponding to the third cell group) as the second cell group specified based on the first scattered light information and the fluorescence information, In 3 specifying means, in order to specify the 4th cell group, the scattergram which makes 2 axis the 2nd scattered light information (side scattered light intensity) and fluorescence information (fluorescence intensity) is created. The cells included in the first cell group, included in the second cell group (substantially corresponding to the third cell group here) and included in the fourth cell group are counted, and the count result is output to the output unit 7. Output to.

  The “myeloblast count result” in the above embodiments includes the number of myeloblasts in the sample, the number of myeloblasts per unit volume (concentration), the ratio of myeloblasts to total leukocytes, and the like. The control unit 6 can output at least one of these.

[Hematological sample]
As a hematological sample, a sample (sample a) containing a large amount of myeloblasts and a sample (sample b) containing myeloblasts and immature leukocytes were used. Samples a and b contain platelet aggregation.

[Preparation of sample for measurement]
(1) Measurement sample using treatment reagent A (A-1) Hemolytic agent A hemolytic agent having the following composition containing the following components was prepared.
Glycine 19.5g / l
Polyoxyethylene (16) oleyl ether 25.0 g / l
Sodium N-lauroyl sarcosinate 0.75 g / l
HEPES 10 mM
1 l of purified water
Sodium hydroxide pH is 7.0

(A-2) Staining solution A fluorescent dye A represented by the following formula is dissolved in ethylene glycol.

上記溶血剤と血液学的試料を混合し、これに上記染色液を、蛍光色素の最終濃度が２０ｐｐｍとなるように、混合して測定用試料を調製した。

A sample for measurement was prepared by mixing the hemolytic agent and the hematological sample, and mixing the staining solution so that the final concentration of the fluorescent dye was 20 ppm.

(2) Sample for measurement using treatment reagent B A sample for measurement was prepared in the same manner as in the case of treatment reagent A, except that a hemolytic agent having the following composition was used.
Xylitol 37.0 g / l
Polyoxyethylene (16) oleyl ether 25.0 g / l
Sodium N-lauroyl sarcosinate 0.75 g / l
HEPES 10 mM
1 l of purified water
Sodium hydroxide pH is 7.0

[Measurement]
Example 1
The measurement sample prepared by mixing the hematological sample a and the processing reagent B and reacting at 33 ° C. for 5 seconds is introduced into the flow cell, and forward scattered light with a flow cytometer (light source: red semiconductor: wavelength: 633 nm), Side scattered light and fluorescence were measured. The measurement results are represented by a first scattergram (FIG. 13A) having two axes of forward scattered light intensity and side scattered light intensity, and a second scattergram (FIG. 13A) having two axes of fluorescence intensity and forward scattered light intensity. 13 (b)).

In FIG. 13A, the appearance area of the first cell group is an area surrounded by a solid line. In FIG. 13B, the appearance region of the second cell group is a region surrounded by a solid line. In FIG. 13 (a), a cell population containing lymphocytes was spread, and a part thereof overlapped the first cell group.
A population of cells contained in both the first cell group and the second cell group is shown in FIG. FIG. 14 is a third scattergram with the side scattered light intensity and the fluorescence intensity as two axes, and the cell populations included in both the first cell group and the second cell group are concentrated in the portion surrounded by the solid line. Appeared.

The number of cells in the region surrounded by the solid line in FIG. 14 was counted, and the ratio to the total white blood cell count was calculated to be 58.5%. On the other hand, hematological sample a was observed with a microscope, and myeloblasts were counted. The ratio of myeloblasts to the total number of white blood cells in the visual field was determined to be 42.0%.
Therefore, according to the measurement method of the present invention, it was confirmed that myeloblasts could be detected with the same accuracy as that observed with a microscope.

Example 2
A measurement sample prepared by treating the hematological sample b with the treatment reagent A at 33 ° C. for 5 seconds is introduced into a flow cell, and forward scattered light, side by flow cytometer (light source: red semiconductor, wavelength: 633 nm) The scattered light and fluorescence were measured. The measurement results are shown in a first scattergram (FIG. 15A) having two axes of forward scattered light intensity and side scattered light intensity, and a second scattergram (FIG. 15A) having two axes of fluorescence intensity and forward scattered light intensity. 15 (b)).

In FIG. 15A, the appearance region of the first cell group is a region surrounded by a solid line. In FIG. 15B, the appearance area of the second cell group is an area surrounded by a solid line.
A population of cells included in both the first cell group and the second cell group is shown in FIG. FIG. 16 is a third scattergram with the side scattered light intensity and the fluorescence intensity as two axes, and the cell populations included in both the first cell group and the second cell group are concentrated in the portion surrounded by the solid line. Appeared.

The number of cells in the region surrounded by the solid line in FIG. 16 was counted, and the ratio to the total white blood cell count was calculated to be 2.4%. On the other hand, hematological sample a was observed with a microscope, and myeloblasts were counted. The ratio of myeloblasts to total leukocytes was 2.5%.
Therefore, according to the measurement method of the present invention, it was confirmed that myeloblasts can be detected with the same degree of accuracy as microscopic observation, and that myeloblasts can be detected with high accuracy, particularly distinguishing from immature granulocytes.

6 Control unit
7 Display section (output section)
21 Light source 26 Forward scattered light detector 29 Side scattered light detector 31 Fluorescence detector

Claims (5)

Sample processing means for damaging the cell membranes of red blood cells and mature white blood cells contained in the hematological sample, contracting blood cells with damaged cell membranes, and staining with a fluorescent dye capable of staining nucleic acids;
A first scattered light information, second scattered light information from the first scattered light based on the different scattered light angles generated by irradiating the excitation light before Symbol fluorescent dye to the processing Gana has been sample, fluorescence information Obtaining means for obtaining and ; and
Control means for performing analysis for counting myeloblasts based on the first scattered light information and the second scattered light information
Including
The control means includes
A process of identifying a first cell group including myeloblasts based on the first scattered light information and the second scattered light information, and a second process including myeloblasts based on the first scattered light information and the fluorescence information. processing for identifying the cell group, and the cells contained in contained and the second cell group in the first cell group executes a process of counting as myeloblast, measuring apparatus hematological sample. The first cell group is a cell group that appears in an appearance candidate region of myeloblast set in a first scattergram having the first scattered light information and the second scattered light information as two axes,
The second cell group is a cell group that appears in a myeloblast appearance candidate region set in a second scattergram having the first scattered light information and the fluorescence information as two axes.
The measuring apparatus according to claim 1 . The counting means expands the cells contained in the first cell group and the second cell group into a third scattergram having the fluorescence information and the second scattered light information as two axes, The measuring apparatus according to claim 1 or 2 , which is means for counting cells appearing in the third scattergram as myeloblasts. Claim further comprising a display unit for displaying at least one of the first scattergram cells have emerged that and included in the cell group included in the second cell group, and the myeloblast count results 1 The apparatus according to any one of 3 to 4 . Measurement apparatus according to any one of claims 1 to 4, further comprising a light source for irradiating the excitation light.

Images